trastuzumab deruxtecan
daiichi sankyo,astrazeneca
['destiny,lung,4', 'lung', 'nsclc', 'destiny,lung02', 'sclc']
dose matters !!! destiny-lung02 trial. same efficacy, less toxicity including pneumonitis in her2 mut #nsclc with 5.4 vs 6.4 dose. should be the standard dose. please include patient in destiny-lung04 trial (exp arm dose is 5.4) #esmo22 
MD, PhD, Prof of Respiratory Medicine, Thoracic Oncology Specialist @CHUdeToulouse, @IUCTOncopoleICR; Researcher, INSERM @crctoncopole #LCSM ????? ?? ??